4,949 Shares in Solventum Co. (NYSE:SOLV) Bought by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC bought a new stake in Solventum Co. (NYSE:SOLV) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,949 shares of the company’s stock, valued at approximately $345,000.

Several other hedge funds also recently bought and sold shares of SOLV. Copeland Capital Management LLC bought a new stake in shares of Solventum in the 3rd quarter valued at approximately $26,000. Blue Trust Inc. bought a new stake in Solventum in the third quarter worth approximately $538,000. QV Investors Inc. increased its stake in shares of Solventum by 59.4% during the 3rd quarter. QV Investors Inc. now owns 250,562 shares of the company’s stock worth $17,469,000 after purchasing an additional 93,370 shares during the last quarter. HTLF Bank bought a new position in shares of Solventum during the 3rd quarter valued at $222,000. Finally, Swedbank AB lifted its stake in shares of Solventum by 20.3% in the 3rd quarter. Swedbank AB now owns 107,197 shares of the company’s stock valued at $7,474,000 after purchasing an additional 18,108 shares during the last quarter.

Solventum Price Performance

Shares of SOLV opened at $73.19 on Friday. The stock’s 50-day moving average price is $67.31 and its 200 day moving average price is $61.27. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, August 8th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, analysts predict that Solventum Co. will post 6.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating on the stock. Wells Fargo & Company reduced their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. The Goldman Sachs Group increased their price target on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Morgan Stanley reduced their price objective on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $64.33.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.